Figure 5.

Olaparib alone or in synergism with PD173074 suppresses the oncogenic cancer stem cell-like phenotype of PDAC cells through an apoptosis-related impairment of DNA repair. (A) Tumorsphere formation assay images and histograms showing the effect of PD173074 and/or olaparib on the tumorsphere formation efficiency of the PANC-1 or SUIT-2 cells. (B) Representative colony formation assay data (left) and graph (right) showing the effect of PD17374 and/or olaparib on the number of colonies formed by PANC-1 or SUIT-2 cells. (C) Immunofluorescence images and histograms of γ-H2AX (red), RAD51 (green), and nuclear DAPI (blue) staining in PANC-1 cells treated with PD173074 and/or olaparib compared with the control. Scale bar, 10 μm. (D) Downregulation of FGFR1, Sox2, and Nanog protein expression levels in PD173074-treated Panc-1 cells as determined by Western blot analysis. β-actin was used as a loading control. * p < 0.05